0.1% Lodoxamide Tromethamine對眼睛過敏性疾病的臨床效果評估

Abstract

Lodoxamide tromethamine is a topical medication which inhibits both mast cell degranulation and eosinophil chemotaxis. This dural mechanism is relatively new to eyedrops and is advantageous to treatment of ocular allergic disorders. Thirty patients including vernal conjunctivitis, allergic conjunctivitis, and soft contact lens related giant papillary conjunctivitis were treated with lodoxamide eyedrops four times a day for two months without using additional steroids throughout the course. Lodoxamide demonstrated significantly subjective and objective improvement on several follow-up visits in the ocular symptoms and signs. Also thirty ocular allergic patients were treated with lodoxamide in one eye and 2% sodium cromoglycate in another eye. In this comparative study versus 2% sodium cromoglycate, lodoxamide demonstrated slightly better on the fast onset of action and milder intensity on the stinging sensation upon drug instillation. After one month treatment period, lodoxamide and 2% sodium cromoglycate showed no obvious statistical difference on the improvement of ocular symtoms and signs.